Hepatitis B virus markers in anti‐HBc only positive individuals*

Journal of Medical Virology - Tập 64 Số 3 - Trang 312-319 - 2001
Bernard Weber1,2, Walter Melchior3, Ralph Gehrke3, Hans Wilhelm Doerr1, Annemarie Berger1, Holger F. Rabenau1
1Institut für Med. Virologie, Universitätskliniken Frankfurt, Germany
2Laboratoires Réunis Kutter-Lieners-Hastert, Junglinster, Luxembourg
3Roche Diagnostics, Penzberg, Germany

Tóm tắt

Abstract

Isolated reactivity to hepatitis B virus (HBV) core antigen (anti‐HBc) is observed relatively frequently in immunocompromised individuals, intravenous drug abusers (IVDA), and in the presence of HCV infection. The reason for the lack of HBsAg is not clear. The aim of the present study was to investigate which factors (genetic variability of S gene, low‐level HBsAg, and immune complexes may be responsible for the failure of HBsAg detection with commercial HBsAg screening assays. Dilution series of two recombinant HBsAg escape mutants and dilutions of serum samples from chronic HBV carriers with multiple insertions in the a determinant and different HBsAg subtypes were tested with a highly sensitive assay that detects wild‐type HBsAg (Elecsys HBsAg, Roche Diagnostics, Penzberg, Germany) and two assays that detect HBV wild‐type and escape mutants (Murex HBsAg Version 3, Murex and Enzygnost HBsAg 5.0, Dade Behring, Marburg, Germany). Elecsys HBsAg showed in comparison to Murex HBsAg Version 3 and Enzygnost HBsAg 5.0 a reduced sensitivity for escape mutant detection. On the other hand, the best performance for HBsAg subtype detection was obtained with Elecsys HBsAg. In the second part of the study, a selected panel of isolated anti‐HBc reactive (n = 104) serum samples (AxSYM Core) was submitted to testing by Elecsys HBsAg, Murex HBsAg Version 3, Enzygnost HBsAg 5.0, and HBsAg detection after immune complex dissociation (ICD) and anti‐HBs determination with two different assays (AxSYM Ausab and Elecsys Anti‐HBs). To assess the specificity of anti‐HBc test results, all the samples were tested by a second anti‐HBc assay (Elecsys Anti‐HBc). Quantitative HBV DNA detection was undertaken with a commercially available HBV PCR assay (Amplicor HBV Monitor). HCV infection was present in 65.4% of anti‐HBc only reactive individuals. Five AxSYM Core positive samples were negative by Elecsys Anti‐HBc. Overall, 15 (14.4%) AxSYM Ausab negative samples gave positive results with Elecsys Anti‐HBs (median value: 21 IU/ml). No low‐level HBsAg carrier was detected among the isolated anti‐HBc reactive individuals with Elecsys HBsAg. There was no evidence for the presence of immune complexes. Only one sample was repeatedly reactive by the Murex HBsAg, suggesting that the a mutant form of HBsAg was responsible for the isolated anti‐HBc reactivity, however neutralisation assay was not interpretable and HBV DNA PCR was negative. Fifteen (14.4%) anti‐HBc only positive individuals were HBV DNA carriers with concentrations ranging from 800 to more than >4,000,000 copies of viral DNA/ml. In conclusion, the most probable explanations for isolated anti‐HBc reactivity in our study group are a possible interference of HBsAg synthesis by HCV infection (65.4%) and divergence of results of anti‐HBs assays (14.4%). There is no evidence for the presence of low‐level HBsAg carriers and immune complexes. HBsAg mutants cannot be excluded definitively by the test strategy used in the present evaluation. J. Med. Virol. 64:312–319, 2001. © 2001 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/S0168-8278(94)80015-4

10.1016/S0168-8278(98)80017-2

10.1016/S0168-8278(05)80554-9

10.1056/NEJM199907013410104

10.1002/hep.510240304

Carman WF, 1997, Viral hepatitis and liver disease, 108

10.1002/hep.510260640

Caspary G, 1989, Unsatisfactory specificities and sensitivities of six enzyme immunoassays for antibodies to hepatitis B core antigen, J Clin Microbiol, 27, 2067, 10.1128/jcm.27.9.2067-2072.1989

Chu CM, 1998, Low‐level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C infection, J Clin Microbiol, 36, 2084, 10.1128/JCM.36.7.2084-2086.1998

10.1097/00007890-199712150-00013

10.1111/j.1365-2893.1995.tb00068.x

10.1093/infdis/172.5.1191

Gross A, 1993, Der Hepatitis‐serologische Befund “Anti‐HBc allein”, zirkulierende virale DNS und Befund‐Interpretation, Schweizer Medizinische Wochenschrift, 123, 1193

10.1128/JCM.19.4.521-525.1984

Hess G, 1997, Viral hepatitis and liver disease, 974

Hollinger FB, 1996, Virology, 2739

10.1056/NEJM197806222982502

10.1002/hep.1840210202

10.1016/0168-8278(95)80305-X

10.1016/S0168-8278(05)80407-6

10.7326/0003-4819-103-1-21

10.1002/hep.1840080411

10.1002/hep.1840150503

10.1006/viro.1994.1127

Rabenau H, 1996, How accurate is serologic testing of plasma pools for hepatitis B virus surface antigen, anti‐human immunodeficiency virus 1 and 2, and anti‐Hepatitis C virus?, Infusionstherapie Transfusionsmedizin, 23, 124

Rakela J, 1980, Viral hepatitis after transfusion with blood containing antibody to hepatitis B core antigen, Gastroenterology, 78, 1318

Robertson EF, 1991, Characterisation of a reduction‐sensitive factor from human plasma responsible for false activity in competitive assays for antibody to hepatitis B core antigen, J Clin Microbiol, 29, 605, 10.1128/jcm.29.3.605-610.1991

Sällberg M, 1989, Enzyme immunoassay for anti‐hepatitis core (HBc) immunoglobulin G1 and significance of low‐level results in competitive assays for anti‐HBc, J Clin Microbiol, 27, 849, 10.1128/jcm.27.5.849-853.1989

10.1016/S0168-8278(05)80207-7

Scheitlin TH, 1992, Infektionen mit den Hepatitisviren HAV, HBV und HCV sowie mit dem AIDS Virus HIV bei Drogenabhängigen der Cassenszene Zürichs: eine Prävalenzstudie, Schweizer Medizinische Wochenschrift, 120, 621

Schifan RB, 1993, Significance of isolated hepatitis B core antibody in blood donors, Arch Intern Med, 153, 2261, 10.1001/archinte.1993.00410190107012

10.1002/(SICI)1096-9071(200002)60:2<113::AID-JMV2>3.0.CO;2-0

10.1056/NEJM198312153092413

10.1046/j.1537-2995.1988.28488265275.x

10.1093/infdis/165.5.831

10.1093/infdis/170.2.358

10.1128/JVI.67.10.5823-5832.1993

10.1086/513918

10.1006/clin.1997.4477

10.1172/JCI116148

Weare JA, 1991, Improvement in the specificity of assays for the detection of antibody to hepatitis B core antigen, J Clin Microbiol, 29, 600, 10.1128/jcm.29.3.600-604.1991

Weber B, 1996, Bedeutung von anti‐HBc‐IgM für die Diagnose und Verlaufskontrolle der Hepatitis B: aktuelle Entwicklungen, Laboratoriumsmedizin, 20, 390

10.1159/000024911

Weber B, 1999, Improved detection of Hepatitis B surface antigen (HBsAg) with a new rapid automated assay, J Clin Microbiol, 37, 2639, 10.1128/JCM.37.8.2639-2647.1999

Weinberger KM, 1997, Viral hepatitis and liver disease, 138

Yamamoto K, 1994, Naturally occuring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen, J Virol, 68, 2671, 10.1128/jvi.68.4.2671-2676.1994

10.1016/S0140-6736(00)02132-2

Thông tin
Thông tin xuất bản

Journal of Medical Virology

Tập 64 Số 3

312-319

Thông tin tác giả